Entero Therapeutics, Inc.
Entero Therapeutics, Inc. (ENTO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ENTO · as of Jun 8, 2026
Key Statistics
Explore Entero Therapeutics, Inc. Data
ento stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
ento competitorsENTO
ALLR
ASBP
ATHA
BCTX
CINGStock Performance
Full HistoryAbout Entero Therapeutics, Inc.
Entero Therapeutics, Inc. a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering an…
what is entero therapeutics, inc. · ento stock overview · entero therapeutics, inc. company profile · who is entero therapeutics, inc. ceo · ento NASDAQ · entero therapeutics, inc. headquarters · entero therapeutics, inc. business segments
About Stock Overview & Key Data
Entero Therapeutics, Inc. (ENTO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 11, 2016. As of the latest trading session, ENTO stock price is $2.85, with a market capitalization of $13.6M. The stock has returned +92.57% over the past 12 months and -44.55% year-to-date.
According to 1 Wall Street analysts, the consensus rating for Entero Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Entero Therapeutics, Inc. reported revenue of $36251.00 and net income of -$6.6M. For detailed data — including Entero Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Entero Therapeutics, Inc. (ENTO) stock price is $2.85. The stock is traded on NASDAQ under the ticker symbol ENTO. The 52-week range is $0.97 – $5.84.